Navigation Links
Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility

NEW YORK and SHANGHAI, March 7, 2011 /PRNewswire-Asia/ -- Bristol-Myers Squibb Company (NYSE: BMY) and WuXi PharmaTech (NYSE: WX) today announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.

Under the agreement, WuXi will build, equip and operate a dedicated, fully cGMP-compliant 25,000-square-foot analytical testing facility in Shanghai to store and test stability samples and to perform other services for Bristol-Myers Squibb. WuXi will also employ a dedicated staff for stability testing, sample management, analytical testing, pharmaceutical science, quality assurance, metrology, and other services, including stability data reporting in support of all global dossier submissions by Bristol-Myers Squibb.

"This new agreement expands our already productive relationship with Bristol-Myers Squibb, a valued customer for many years," said Ge Li, Ph.D., chairman and chief executive officer of WuXi PharmaTech. "We will continue to help them to improve their R&D productivity with our innovation-driven, cost-effective and fully integrated R&D service platform."

"WuXi PharmaTech is an important partner for Bristol-Myers Squibb's research and development organization," said Mark Powell, Ph.D., senior vice president, Non-Clinical Development, Bristol-Myers Squibb. "This agreement will expand the scope of our relationship with WuXi and enhance the presence of Bristol-Myers Squibb in China. It is also an example of our R&D organization executing our company's BioPharma model by using selective integration to leverage the strengths and talents of both Bristol-Myers Squibb and a valued partner."

About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, developand deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit or follow us on Twitter at

About WuXi PharmaTechWuXi PharmaTech is a leading pharmaceutical, biotechnology and medical-device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical-device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical-device R&D process. For more information, please visit: . For more information, please contact:Bristol-Myers SquibbMedia: Jennifer Fron MauerTel:
+1-609-252-6579Investor Relations:Teri LoxamTel:
+1-609-252-3368Timothy PowerTel:   +1-609-252-7509WuXi PharmaTechMedia: Email: Stephanie_Liu@wuxiapptec.comTel:
+86-21-50464362Investor Relations: Email: Ron_Aldridge@wuxiapptec.comTel:

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
2. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
3. Top Bristol-Myers Squibb Executive Joins Patton Boggs
4. Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
5. Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb
6. Bristol-Myers Squibb Sued for Denying Employees Overtime Pay
7. Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
8. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
11. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
Post Your Comments:
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):